多发性骨髓瘤
嵌合抗原受体
临床试验
癌症研究
耐火材料(行星科学)
抗原
医学
生物
癌症
免疫学
内科学
免疫疗法
天体生物学
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2017-06-07
卷期号:7 (8): OF9-OF9
被引量:4
标识
DOI:10.1158/2159-8290.cd-nb2017-088
摘要
Preliminary results from an ongoing phase I clinical trial in China suggest that chimeric antigen receptor T cells engineered to home in on a protein called BCMA may be a potent therapeutic option for multiple myeloma. The therapy was well tolerated and induced complete, durable responses in patients with relapsed/refractory disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI